Abstract CT184: Emerging evidence of activity of BLU-945 in patients with advanced EGFR-mutant NSCLC utilizing circulating tumor DNA (ctDNA) in the phase 1/2 SYMPHONY study | Citedby Results | Cancer Research | American Association for Cancer Research

Skip to Main Content

Skip Nav Destination

Abstract CT184: Emerging evidence of activity of BLU-945 in patients with advanced EGFR-mutant NSCLC utilizing circulating tumor DNA (ctDNA) in the phase 1/2 SYMPHONY study

Cancer Res (2022) 82 (12_Supplement): CT184.

This article has been cited by the following articles in journals that are participating in CrossRef Cited-by Linking.

Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance

Kai Fu
Fachao Xie
Fang Wang
Liwu Fu

Journal of Hematology & Oncology (2022) 15 (1)

Overcoming C797S mutation: The challenges and prospects of the fourth-generation EGFR-TKIs

Hong-Yi Zhao
Xiao-Xiao Xi
Minhang Xin
San-Qi Zhang

Bioorganic Chemistry (2022) 128: 106057.

Combatting acquired resistance to osimertinib in EGFR-mutant lung cancer

Jiyun Lee
Zofia Piotrowska
Ross Soo
Byoung Chul Cho
Sun Min Lim

Therapeutic Advances in Medical Oncology (2022) 14: 175883592211440.